1. [Neuroendocrine small-cell bladder cancer: our experience].
- Author
-
Ruoppolo M, Pezzica E, Milesi R, Corti D, Mercurio P, and Fragapane G
- Subjects
- Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin administration & dosage, Carcinoma, Neuroendocrine complications, Carcinoma, Neuroendocrine drug therapy, Carcinoma, Neuroendocrine mortality, Carcinoma, Neuroendocrine secondary, Carcinoma, Neuroendocrine surgery, Carcinoma, Small Cell complications, Carcinoma, Small Cell drug therapy, Carcinoma, Small Cell mortality, Carcinoma, Small Cell secondary, Carcinoma, Small Cell surgery, Combined Modality Therapy, Cystectomy, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Disease Progression, Fatal Outcome, Gastrointestinal Hemorrhage etiology, Hematuria etiology, Humans, Intestinal Neoplasms complications, Intestinal Neoplasms secondary, Leukemia, Lymphocytic, Chronic, B-Cell, Liver Neoplasms secondary, Lymph Node Excision, Male, Middle Aged, Neoplasms, Second Primary, Peritoneal Neoplasms secondary, Prostatic Neoplasms, Stomach Neoplasms, Survival Rate, Urinary Bladder Neoplasms complications, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms surgery, Gemcitabine, Carcinoma, Neuroendocrine pathology, Carcinoma, Small Cell pathology, Urinary Bladder Neoplasms pathology
- Abstract
Introduction: Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.35-0.70% of all bladder tumors. The small-cell carcinoma represents the most frequent histologic variant described. Small-cell carcinoma is an epithelial tumor associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinoma. The overall survival rate at 5 years does not exceed 8%. At the time of presentation 59% of patients have clinical stage >T2 and 56% show metastatic disease. In 50% of the patients, fatal progression occurs within 6 months. Local recurrence after radical surgery occurred in 50-70% of cases., Patients and Methods: We report three cases of pure neuroendocrine small-cell bladder cancer. Hematuria was the most common presenting symptom. Local advanced disease was present in all the cases with stage >T2, metastatic disease in 1 case, lymph node involvement and ureteral bilateral obstruction in 2. Two patients were treated by radical cystectomy, bilateral pelvic limph node resections and urinary derivation. Platinum-based adjuvant chemotherapy was proposed but only two patients received the treatment. One patient with liver metastasis was managed only by extensive TUR and support regimen., Results: In 2 patients residual or relapsed cancer reappered within 2 months after surgery. All of the three patients died of metastatic disease at 5, 7, and 13 months. Median overall survival was 7 months. The most common site of relapse and spread of disease was the peritoneum and intestinal tract, and the reason of death was uncontrolled acute hemorrhage from gastro-intestinal district., Conclusions: In the absence of a prospective study, and because of the rarity of the disease, the best treatment for small-cell bladder cancer remains uncertain. Neoadjuvant chemotherapy with platinum regimen plus aggressive surgical approach will be the treatment of choice. The association of chemotherapy and radiotherapy should also be considered.
- Published
- 2010